Intersect ENT, Inc. (XENT): Price and Financial Metrics

Intersect ENT, Inc. (XENT): $28.24

0.00 (0.00%)

POWR Rating

Component Grades














  • XENT scores best on the Growth dimension, with a Growth rank ahead of 71.6% of US stocks.
  • XENT's strongest trending metric is Value; it's been moving down over the last 179 days.
  • XENT ranks lowest in Sentiment; there it ranks in the 13th percentile.

XENT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for XENT is -1.55 -- better than merely 3.73% of US stocks.
  • XENT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.09% of US stocks.
  • With a year-over-year growth in debt of 74.54%, Intersect ENT Inc's debt growth rate surpasses 87.17% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Intersect ENT Inc are DHX, ATRC, JMIA, ROG, and ICUI.
  • XENT's SEC filings can be seen here. And to visit Intersect ENT Inc's official web site, go to

XENT Valuation Summary

  • XENT's price/sales ratio is 8.8; this is 22.47% lower than that of the median Healthcare stock.
  • XENT's price/earnings ratio has moved up 3.3 over the prior 86 months.
  • XENT's price/sales ratio has moved down 1.8 over the prior 86 months.

Below are key valuation metrics over time for XENT.

Stock Date P/S P/B P/E EV/EBIT
XENT 2021-08-31 8.8 21.8 -13.3 -14.7
XENT 2021-08-30 8.8 21.8 -13.3 -14.7
XENT 2021-08-27 9.0 22.1 -13.5 -14.9
XENT 2021-08-26 9.0 22.1 -13.5 -14.9
XENT 2021-08-25 9.0 22.1 -13.5 -14.9
XENT 2021-08-24 9.0 22.1 -13.5 -14.9

XENT Growth Metrics

    Its 3 year revenue growth rate is now at 70.11%.
  • The 3 year price growth rate now stands at 79.48%.
  • The 3 year net cashflow from operations growth rate now stands at 20.35%.
XENT's revenue has moved down $3,674,000 over the prior 34 months.

The table below shows XENT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 106.748 -59.467 -159.635
2021-09-30 104.305 -54.394 -88.678
2021-06-30 102.625 -45.884 -68.294
2021-03-31 85.056 -46.51 -74.817
2020-12-31 80.554 -35.694 -72.319
2020-09-30 84.08 -32.347 -60.079

XENT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XENT has a Quality Grade of C, ranking ahead of 64.28% of graded US stocks.
  • XENT's asset turnover comes in at 0.481 -- ranking 98th of 186 Medical Equipment stocks.
  • IART, CODX, and ALGN are the stocks whose asset turnover ratios are most correlated with XENT.

The table below shows XENT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.481 0.707 -0.561
2021-06-30 0.506 0.675 -0.423
2021-03-31 0.432 0.620 -0.416
2020-12-31 0.452 0.624 -0.441
2020-09-30 0.531 0.657 -0.399
2020-06-30 0.578 0.697 -0.468

XENT Price Target

For more insight on analysts targets of XENT, see our XENT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.21 Average Broker Recommendation 2.06 (Hold)

XENT Stock Price Chart Interactive Chart >

Price chart for XENT

XENT Price/Volume Stats

Current price $28.24 52-week high $28.25
Prev. close $28.24 52-week low $15.92
Day low $28.23 Volume 837,100
Day high $28.25 Avg. volume 351,526
50-day MA $27.80 Dividend yield N/A
200-day MA $27.27 Market Cap 954.91M

Intersect ENT, Inc. (XENT) Company Bio

Intersect ENT provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company was founded in 2003 and is based in Menlo Park, California.

XENT Latest News Stream

Event/Time News Detail
Loading, please wait...

XENT Latest Social Stream

Loading social stream, please wait...

View Full XENT Social Stream

Latest XENT News From Around the Web

Below are the latest news stories about Intersect ENT Inc that investors may wish to consider to help them evaluate XENT as an investment opportunity.

Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Havens Advisors Llc Buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Sells , ,

New York, NY, based Investment company Havens Advisors Llc (Current Portfolio) buys BHP Group PLC, CyrusOne Inc, NeoPhotonics Corp, Rogers Corp, Triple-S Management Corp, sells , , , Cloudera Inc, during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Havens Advisors Llc.

Yahoo | January 31, 2022

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

MENLO PARK, Calif., January 25, 2022--Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Yahoo | January 25, 2022

Intersect ENT, Inc. (NASDAQ:XENT) Expected to Announce Quarterly Sales of $37.13 Million

Analysts expect that Intersect ENT, Inc. (NASDAQ:XENT) will post sales of $37.13 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Intersect ENTs earnings, with estimates ranging from $36.53 million to $37.82 million. Intersect ENT reported sales of $28.23 million in the same quarter last year, which would []

Transcript Daily | December 21, 2021

Read More 'XENT' Stories Here

XENT Price Returns

1-mo 1.55%
3-mo 3.33%
6-mo 4.79%
1-year 57.33%
3-year 13.41%
5-year 12.29%
YTD 3.41%
2021 19.26%
2020 -8.03%
2019 -11.64%
2018 -13.02%
2017 167.77%

Continue Researching XENT

Want to see what other sources are saying about Intersect ENT Inc's financials and stock price? Try the links below:

Intersect ENT Inc (XENT) Stock Price | Nasdaq
Intersect ENT Inc (XENT) Stock Quote, History and News - Yahoo Finance
Intersect ENT Inc (XENT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0352 seconds.